Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 69, Issue -, Pages 786-789Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2013.09.031
Keywords
Aminomorphinan; MOR/DOR agonist; Opioid; Analgesia; Respiratory depression; Cinnamoyl morphinamine
Categories
Funding
- National Institute on Drug Abuse [DA034106-01, DA06241, DA02165, DA07242]
- National Cancer Institute [CA08748]
- Technology Development Fund of Memorial Sloan-Kettering Cancer Center
- Predoctoral Fellowship in Pharmacology from the PhRMA Foundation
Ask authors/readers for more resources
Aminomorphinans are a relatively young class of opioid drugs among which substances of high in vitro efficacy and favorable in vivo action are found. We report the synthesis and pharmacological evaluation of novel 6 beta-acylaminomorphinans. 6 beta-Morphinamine and 60-codeinamine were stereoselectively synthesized by Mitsunobu reaction. The aminomorphinans were subsequently acylated with diversely substituted cinnamic acids. In vitro binding studies on cinnamoyl morphinamines showed moderate affinity for all opiate receptors with some selectivity for mu opioid receptors, while cinnamoyl codeinamines only showed affinity for mu opioid receptors. In vivo analgesia studies showed significant analgesic activity of 6 beta-cinnamoylmorphinamine mediated by mu and delta receptors. The lead compound was found to be roughly equipotent to morphine (ED50 3.13 +/- 1.09 mg/kg) but devoid of the dangerous side-effect respiratory depression, a major issue associated with traditional opioid therapy. (C) 2013 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available